Systematic review for the serological testing for cold agglutinins: The BEST collaborative study

Affiliations

¹ Center for Clinical Transfusion Research, Sanquin Research, Amsterdam, The Netherlands.
² Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
³ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
⁴ Medical Affairs and Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.
⁵ Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
⁶ Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
⁷ Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA.
⁸ Department of Laboratory Medicine and Pathology, Center for Regenerative Biotherapeutics, Mayo Clinic, Rochester, Minnesota, USA.
⁹ NHS Blood and Transplant, Oxford University Hospitals NHS Foundation Trust, and the University of Oxford, Oxford, UK.
¹⁰ Department of Laboratory Medicine and Pathology, University of Washington, Washington, USA.
¹¹ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
¹² Centre for Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.

Marit Jalink et al. Transfusion. 2024 Jul.

. 2024 Jul;64(7):1331-1349.

doi: 10.1111/trf.17842. Epub 2024 Apr 20.

¹ Center for Clinical Transfusion Research, Sanquin Research, Amsterdam, The Netherlands.
² Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
³ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
⁴ Medical Affairs and Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.
⁵ Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
⁶ Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
⁷ Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA.
⁸ Department of Laboratory Medicine and Pathology, Center for Regenerative Biotherapeutics, Mayo Clinic, Rochester, Minnesota, USA.
⁹ NHS Blood and Transplant, Oxford University Hospitals NHS Foundation Trust, and the University of Oxford, Oxford, UK.
¹⁰ Department of Laboratory Medicine and Pathology, University of Washington, Washington, USA.
¹¹ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
¹² Centre for Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.

No abstract available

Keywords: AIHA/drug‐induced IHA; immunohematology (RBC serology, blood groups); transfusion practices (adult).

References

1. Berentsen S. How I treat cold agglutinin disease. Blood. 2021;137:1295–1303.
1. Berentsen S. New insights in the pathogenesis and therapy of cold agglutinin‐mediated autoimmune hemolytic anemia. Front Immunol. 2020;11:590.
1. Roth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, et al. Sutimlimab in cold agglutinin disease. N Engl J Med. 2021;384:1323–1334.
1. Roth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, et al. Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1‐year interim follow‐up results. Haematologica. 2022;107:1698–1702.
1. Roth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, et al. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo‐controlled phase 3 CADENZA trial. Blood. 2022;140:980–991.